← Back to Search

Behavioral Intervention

Stress Management Program for Von Hippel-Lindau Syndrome

N/A

Waitlist Available

Led By Giselle Perez, PhD

Research Sponsored by Massachusetts General Hospital

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Confirmed diagnosis of VHL

Be older than 18 years old

Must not have

Unwilling or unable to participate in study sessions delivered via Partners Telehealth videoconferencing

Timeline

Screening 3 weeks

Treatment Varies

Follow Up post-treatment completion (treatment is approximately 2 months)

Awards & highlights

No Placebo-Only Group

Summary

This trial will study how an adapted stress management program can help people with a chronic illness better cope with their condition. #chronicillness #stressmanagement

Who is the study for?

This trial is for adults over 18 with a confirmed diagnosis of Von Hippel-Lindau (VHL) disease, which is a genetic disorder. Participants must be able to engage in videoconferencing sessions and not have any medical or psychiatric conditions that would prevent full participation as assessed by a physician.

What is being tested?

The study tests an adapted Relaxation Response Resiliency Program (3RP-VHL), designed to help VHL patients cope better with their condition. It's about learning stress management techniques specifically tailored for those living with this chronic illness.

What are the potential side effects?

Since the intervention involves stress management and resilience training, there are no direct physical side effects like you'd expect from medication. However, participants may experience emotional discomfort when discussing personal challenges related to VHL.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have been diagnosed with Von Hippel-Lindau disease.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I am willing and able to attend sessions through video calls.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ post-treatment completion (treatment is approximately 2 months)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~post-treatment completion (treatment is approximately 2 months)

This trial's timeline: 3 weeks for screening, Varies for treatment, and post-treatment completion (treatment is approximately 2 months) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

3RP-VHL Acceptability: Five Questions

3RP-VHL Feasibility: Percent of Identified Eligibles Who Enroll

3RP-VHL Feasibility: Proportion of Participants Completing the 3RP-VHL Program

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: 3RP-VHLExperimental Treatment1 Intervention

* An adapted version of the 3RP (3RP-VHL) for individuals with VHL. The adapted program incorporates the three prongs of the 3RP: RR elicitation, stress awareness, and adaptive strategies. It will be delivered in weekly sessions over the course of approximately 8 weeks. * Complete pre- and post-intervention surveys.

0 / 2Eligibility criteria met